Teijin's Novel Gout Drug To Launch In Europe

SHANGHAI - Teijin Pharma will launch xanthine oxidase inhibitor TMX67, its novel gout drug, in Europe, the company announced Feb. 25.The Tokyo-based company received a positive recommendation Feb. 21 from the European Medicines Agency's Committee for Medicinal Products for Human Use